You know, I don't think we were asking at all for additional funds or money from the federal government. Walter actually made that fairly clear that this is one of the unique parts of our submission, that we're not looking for incremental money. We're looking for support for key policy changes that help create Canada as an attractive environment on the global R and D stage.
The steps forward with the free trade agreement with Europe that have enhanced the intellectual property regime for Canada helped us level the playing field with Europe and the U.S. and other countries. So we're asking for support from this committee and the House to move that forward.
There are key programs already in place that the government funds, if you think of CIHR or the SR and ED tax credits. These are all very competitive programs that we look to take advantage of, and it's not just us, the large pharma companies. It's also the small biotech ecosystem across this country that those programs are absolutely critical for. The future of innovation in Canada rests a lot on the shoulders of the small biotech companies and the partnerships that are created between companies like ourselves at Johnson and Johnson and those small companies as they emerge.